

## Company Overview

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient's own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, next-generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

## Adaptimmune Reports First Quarter Financial Results and Business Update

May 6 2021, 7:30 AM EDT

## Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Apr 27 2021, 4:30 PM EDT

## Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

Apr 22 2021, 8:00 AM EDT

## Stock Overview

|               |                  |
|---------------|------------------|
| Symbol        | ADAP             |
| Exchange      | Nasdaq           |
| Market Cap    | 733.87m          |
| Last Price    | \$4.72           |
| 52-Week Range | \$3.54 - \$13.40 |

05/10/2021 04:00 PM EDT

## Investor Relations

T: 215-825-9306  
[IR@adaptimmune.com](mailto:IR@adaptimmune.com)

## Adaptimmune Therapeutics plc

351 Rouse Boulevard  
Philadelphia, PA 19112  
USA

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.